Our Partners

MSKCC2 logo
In September 2016, we entered into a collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC) for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines. Current cellular immunotherapies involve multi-step manufacturing that is logistically challenging and complex, and significant hurdles remain to ensure that patient-specific T-cell immunotherapies can be efficiently and consistently manufactured, and safely and reliably delivered at the scale necessary to support broad patient access and wide-spread commercialization. This three-year collaboration aims to leapfrog the current patient-specific approach to T-cell immunotherapy by uniting research, preclinical development and manufacturing work currently being conducted independently at Fate Therapeutics and Memorial Sloan Kettering to accelerate the clinical translation of off-the-shelf T-cell product candidates derived from engineered pluripotent cells. Collectively, Fate and MSKCC have amassed significant and complementary expertise necessary to deliver off-the-shelf T-cell immunotherapies, including the engineering, maintenance and expansion of induced pluripotent cell lines and the scalable generation of T cells with enhanced safety profiles and effector functions.

In July 2015, we entered into a collaboration with the University of Minnesota to advance the development of two distinct NK cell cancer immunotherapy programs. Through the first collaboration, we seek to develop an adaptive NK cell therapy product with a unique metabolic program that exhibits long-term persistence in vivo and has an epigenetic profile similar to that of cytotoxic T lymphocytes. The second collaboration is focused on generating iPSC-derived engineered NK cells as cancer immunotherapies. This collaboration combines capabilities and expertise from Fate and the University of Minnesota in an effort to efficiently generate large quantities of cytotoxic NK cells from induced pluripotent cells, including from induced pluripotent cells that have been engineered to express tumor cell-targeting modalities.
In June 2015, we entered into a collaboration with Boston Children’s Hospital to accelerate the development of an immuno-regulatory CD34+ cell-based therapy to treat auto-immune diseases. This collaboration builds upon our discovery of a combination of pharmacologic modulators, which enable the supra physiologic activation of immuno-regulatory proteins, including PD-L1, in human CD34+ cells. We have shown that these programmed CD34+ cells traffic to sites of inflammation and suppress activated T cells. Under the collaboration, we seek to investigate the potential of our programmed CD34+ cell-based immunotherapy to abrogate auto-immune activity in preclinical models of diseases, including Type 1 diabetes.

In May 2015, we entered into a research collaboration and license agreement with Juno Therapeutics to identify small molecule modulators to program the therapeutic properties of genetically-engineered CAR (chimeric antigen receptor) T cell and TCR (T cell receptor) immunotherapies. In striking this strategic collaboration, we have brought together Juno’s scientific and clinical leadership in CAR T and TCR immunotherapy and our expertise in hematopoietic cell biology and cell programming to enhance the therapeutic function of immune cells. Under the collaboration, we seek to identify small molecule modulators of immunological cells, and Juno is responsible for the development and commercialization of genetically-engineered T cell immunotherapies incorporating our modulators.

Partnering Strategy

Academic research collaborations and strategic corporate partnerships are integral to bringing our science and product candidates to patients and their families. Fate is seeking to build on this foundation of partnerships and collaborations by actively considering:

  • Regional corporate collaborations to expand and accelerate development of our product candidates
  • Corporate research and development partnerships that seek to leverage our cell programming technologies for the development of novel cell-based therapies
  • Corporate research and development collaborations, and academic technology in-licensing, that complements our existing interests in developing programmed cellular immunotherapeutics for cancer and immune disorders

For discussion of our licensing opportunities or collaboration interests, please contact BD@fatetherapeutics.com